BOSTON — A regimen of raltegravir and darunavir/ritonavir was noninferior to tenofovir/emtricitabine and darunavir/ritonavir as first-line treatment for treatment-naive patients with HIV, researchers reported here at the 2014 Conference on Retroviruses and Opportunistic Infections.
The NEAT 001/ANRS 143 trial was a randomized, open-label study in which 805 patients were randomly assigned to darunavir (Prezista/Janssen)/ritonavir (Norvir, AbbVie) with either raltegravir (Isentress, Merck) or tenofovir/emtricitabine (Truvada, Gilead Sciences). The patients were followed for 96 weeks. The primary outcome was time to first occurrence of failure. Failure was categorized as virologic or clinical. Virologic failure was defined as change of treatment before week 32 because of viral load decrease <1 log10 copies/mL by week 18, viral load ≥400 copies/mL at week 24 or viral load >50 copies/mL at or after week 32. Clinical failure included death, AIDS or serious non-AIDS event.More »